Table 2.
Univariate analysis for impact on overall survival.
| Categorical variable | Hazard ratio (95% CI) | p-value | |
|---|---|---|---|
| Gender | Male | 1 | |
| Female | 0.838 (0.565–1.243) | 0.3796 | |
| Race | White | 1 | |
| Hispanic | 0.986 (0.541–1.798) | 0.964 | |
| African American | 1.067 (0.605–1.883) | 0.8223 | |
| Other | 1.148 (0.616–2.136) | 0.6643 | |
| Cancer type | Solid | 1 | |
| Hematologic | 0.753 (0.492–1.154) | 0.1931 | |
| Primary cancer | Breast | 1.704 (0.524–5.537) | 0.3755 |
| Gastrointestinal | 0.517 (0.187–1.430) | 0.2038 | |
| Genitourinary | 0.815 (0.198–3.354) | 0.7768 | |
| Gynecologic | 1.492 (0.463–4.811) | 0.5032 | |
| Head and Neck | 2.117 (0.289–15.491) | 0.4601 | |
| Leukemia | 1 | ||
| Lung | 1.471 (0.813–2.660) | 0.202 | |
| Lymphoma | 0.520 (0.296–0.911) | 0.0223 | |
| Melanoma | 0.000 (0.000) | 0.9867 | |
| Renal | 6.707 (0.886–50.760) | 0.0653 | |
| Sarcoma | 1.126 (0.350–3.621) | 0.8419 | |
| Thymus | 0.000 (0.000) | 0.9903 | |
| Advanced cancer | 10.717 (4.345–26.433) | <0.0001 | |
| History of radiotherapy | 1.351 (0.892–2.046) | 0.1549 | |
| Chemotherapy within 1 month | 1.538 (0.892–2.396) | 0.0565 | |
| Tobacco smoker within 1 year | 1.382 (0.988–2.108) | 0.1336 | |
| Hypertension | 0.662 (0.445–0.984) | 0.0416 | |
| Dyslipidemia | 0.791 (0.525–1.192) | 0.2624 | |
| Chronic lung disease | 0.938 (0.488–1.802) | 0.8467 | |
| Diabetes mellitus | 0.643 (0.334–1.239) | 0.1869 | |
| CKD, dialysis–dependent | 2.673 (0.654–10.922) | 0.1709 | |
| cerebrovascular disease | 0.483 (0.153–1.530) | 0.2164 | |
| Coronary artery disease | 0.763 (0.280–2.077) | 0.5959 | |
| Chronic heart failure | 1.069 (0.606–1.886) | 0.8182 | |
| Family history premature CAD | 0.615 (0.249–1.520) | 0.2926 | |
| Aspirin use only | 0.543 (0.281–1.049) | 0.0691 | |
| Clopidogrel use only | 0.275 (0.038–1.980) | 0.2001 | |
| DOAC use only | 1.023 (0.448–2.337) | 0.9569 | |
| Platelet transfusion refractoriness | 1.874 (1.201–2.925) | 0.0057 | |
| Cardiac tamponade on TTE | 1.269 (0.857–1.879) | 0.2337 | |
| Complications | 0.707 (0.224–2.232) | 0.5541 | |
| Procedural guidance modality | Echocardiogram | 0.634 (0.257–1.563) | 0.3224 |
| Fluoroscopy | 0.944 (0.638–1.399) | 0.775 | |
| Combined | 1.108 (0.712–1.725) | 0.6481 | |
| Aspirated fluid appearance | Serous | 1 | |
| Hemorrhagic | 0.814 (0.546–1.214) | 0.3131 | |
| Malignant aspirated fluid | 1.659 (1.117–2.465) | 0.0122 | |
| Age (years) | 1.003 (0.992–1.014) | 0.6026 | |
| Weight (kg) | 0.999 (0.988–1.009) | 0.816 | |
| Height (cm) | 0.988 (0.974–1.002) | 0.1027 | |
| BMI (kg/m2) | 1.008 (0.994–1.022) | 0.2675 | |
| BSA (m2) | 0.826 (0.368–1.855) | 0.6427 | |
| Troponin I (ng/mL) | 0.996 (0.988–1.005) | 0.3961 | |
| Troponin T (ng/mL) | 1.018 (0.959–1.081) | 0.5521 | |
| BNP (pg/mL) | 1.000 (1.000–1.000) | 0.8847 | |
| NT–proBNP (pg/mL) | 1.000 (0.998–1.002) | 0.8009 | |
| Serum creatinine (mg/dL) | 1.000 (0.857–1.166) | 1 | |
| WBC (cells/mL3) | 1.008 (0.975–1.042) | 0.6452 | |
| Hemoglobin (g/dL) | 1.015 (0.901–1.143) | 0.8121 | |
| pRBC administered within 24 h (units) | 1.297 (0.880–1.913) | 0.0.1886 | |
| Platelet count (day 0) (K/mL) | 0.993 (0.989–0.997) | 0.0021 | |
| Grade 1 (75–149 × 103 cells/μL) | 1 | ||
| Grade 2 (50–74 × 103 cells/μL) | 1.276 (0.592–2.753) | 0.5336 | |
| Grade 3 (25–49 × 103 cells/μL) | 1.530 (0.928–2.522) | 0.0959 | |
| Grade 4 (0–24 × 103 cells/μL) | 2.102 (1.288–3.431) | 0.0029 | |
| Platelet administered within 24 h (units) | 1.055 (1.003–1.110) | 0.0374 | |
| INR | 2.583 (1.279–5.219) | 0.0082 | |
| LVEF (%) by TTE | 1.010 (0.987–1.033) | 0.3888 |
SD, standard deviation; CI, confidence interval; BMI, body mass index; BSA, body surface index; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro brain natriuretic peptide; WBC, white blood cell: pRBC, packed red blood cell INR, international normalized ratio; LVEF, left ventricular ejection fraction; TTE, transthoracic echocardiogram. Boldface indicates statistical significance.